Research and Developments

Page 1 of 1812345...10...Last »

February 15, 2017

Another Anti-VEGF Drug Falls Short

Posted in: Latest News, Research and Developments

by Dan Roberts We announced here in December 2016 that Fovista, Ophthotech’s once-promising experimental drug for treatment of wet macular degeneration, failed to show positive results in Phase 3 trials, resulting in a discontinuance of the research. Now, Ohr Pharmaceuticals has announced temporary suspension of a clinical study for its drug candidate, Squalamine, an eye
read more »

January 27, 2017

Trials beginning for Emixustat Treatment of Stargardt Disease

Posted in: Latest News, Research and Developments

Acucela has announced that the first patient has enrolled in a study to evaluate emixustat hydrochloride (“emixustat”) in subjects with Stargardt disease. Approximately 30 subjects will be enrolled at 4 to 6 clinical sites in the United States, with subjects taking oral doses of the drug once daily in the evening for one month. Emixustat
read more »

January 22, 2017

“How soon will my good eye go bad?”

Posted in: Latest News, Research and Developments

This is commonly-asked by people affected with unilateral age-related macular degeneration (AMD). AMD is a chronic and progressive disease, and the chances are good that it will eventually affect both eyes. The question about when that will happen has been addressed by a three-continent study published in January 2017 by the British Journal of Ophthalmology. Researchers
read more »

January 14, 2017

Researchers To Study Telescope Implant For Post-Cataract Patients

Posted in: Latest News, Research and Developments

VisionCare, Inc. has announced FDA approval to study the company’s Implantable Miniature Telescope (IMT) in patients who have been previously treated for cataract. In the study, the new intraocular lens will be removed and replaced with the IMT in order to evaluate the safety and effectiveness of the device. For the past 8 years, the telescope implant has been improving visual acuity and quality of life
read more »

January 6, 2017

Lucentis® Approved for Myopic Macular Degeneration

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

Genentech has announced FDA approval for Lucentis® as a treatment for patients with choroidal neovascularization (CNV) resulting from myopic macular degeneration (MMD), also known as myopic degeneration. Severe myopia (near-sightedness) can cause uncorrectable central vision impairment, and it may advance to total central vision loss from CNV, which is growth and leakage of blood vessels
read more »

December 21, 2016

Fovista® Fails Final Test For Wet AMD Treatment

Posted in: Latest News, Research and Developments

Fovista®, a once-promising experimental drug for treatment of wet macular degeneration, has failed to show positive results in Phase 3 trials. This is surprising, since, on June 14, 2012, Ophthotech Corporation reported a 62% higher relative visual benefit when Fovista (1.5 mg) was used in combination with Lucentis in Phase 2b clinical trials. Based upon those
read more »

December 6, 2016

Photobiomodulation—A New Treatment For Dry AMD?

Posted in: Latest News, Research and Developments

A new non-invasive technology from LumiThera Inc. may help improve vision in  people with dry age-related macular degeneration. Photobiomodulation involves exposure of the retina to light from diodes emitting red, yellow, and infrared wavelengths. Researchers in Switzerland and Toronto recently found that treating eyes three times a week for three weeks improved best corrected visual
read more »

November 22, 2016

Eye Drops for Wet AMD Showing Positive Results

Posted in: Latest News, Research and Developments

Eye drops continue to show promise as future treatments for wet AMD and other eye diseases involving blood vessel growth and hemorrhaging in the retina. In a presentation at the 2015 Ophthalmology Innovation Summit at the American Academy of Ophthalmology. Paul G. Chaney (President and CEO of Panoptica) reported preliminary results from the PAN-90806 clinical
read more »

October 13, 2016

FDA Grants Priority Review for Myopic CNV Treatment

Posted in: Latest News, Research and Developments

Genentech, makers of Lucentis® (ranibizumab injection) for wet AMD, has been approved for Priority Review by the FDA to study Lucentis for the treatment of myopic choroidal neovascularization (mCNV). Also known as degenerative myopia, mCNV is a complication of severe near-sightedness that can lead to uncorrectable visual impairment. The FDA’s approval is based on results from the Phase
read more »

October 13, 2016

RADIANCE Study for Treatment of Myopic Degeneration

Posted in: Research and Developments

RADIANCE is a Phase III, 12-month, randomized, double-masked, multicenter, active-controlled study comparing the efficacy and safety of Lucentis (0.5 mg) versus verteporfin photodynamic therapy (vPDT) in 277 patients with visual impairment due to myopic choroidal neovascularization (mCNV). Patients were randomized into three treatment groups: 106 patients in group I received treatment with Lucentis on study
read more »

Page 1 of 1812345...10...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann